Fluviral(R) now available to Canadian private market customers for 2008-2009 influenza season



    Canadian vaccine manufacturer able to deliver doses ahead of schedule

    MISSISSAUGA, ON, Oct. 9 /CNW/ - GlaxoSmithKline Inc. (GSK) today
announced that it has begun shipment of FLUVIRAL(R) (Influenza Virus Vaccine)
to Canadian private market customers for the 2008-2009 influenza season,
having met and exceeded the contractual timelines for public market
deliveries.
    With the majority of doses already delivered to provinces across Canada,
GSK has also begun to ship vaccine to direct customers, including physicians
and clinics, which will allow customers to begin immunizing patients as soon
as possible.
    "We are pleased to be able to quickly supply influenza vaccine in Canada
for the 2008-2009 season," said Dr. Tjark Reblin, Vice President Medical and
Chief Medical Officer, GlaxoSmithKline Inc. "We are excited to play an
integral part in helping Canadians protect themselves against this serious
infection."
    Production of influenza vaccine this year was complicated by the
introduction of three new influenza strains for the 2008-2009 season:
A/Brisbane/59/2007 (H1N1)-like strain, A/Brisbane/10/2007 (H3N2)-like strain
and B/Florida/4/2006-like strain. Fortunately, this factor did not result in
any delays in delivering doses for the season.

    About Seasonal Influenza

    Influenza, or "the flu," is a respiratory illness that affects millions
of Canadians each year, primarily during the winter months. The flu typically
starts with a headache, chills and cough, followed rapidly by fever, loss of
appetite, muscle aches and fatigue, running nose, sneezing, watery eyes and
throat irritation. Nausea, vomiting and diarrhea may also occur, especially in
children.
    While the majority of those who become sick will recover, influenza
results in an average of 20,000 hospitalizations and 4,000 deaths in Canada
each year. According to the Public Health Agency of Canada, the influenza
vaccine - combined with regular hand washing and proper cough etiquette -
provides the best protection for oneself and others against the influenza
virus.

    About FLUVIRAL(R)

    FLUVIRAL(R) conforms to the current requirements of the World Health
Organization (WHO). FLUVIRAL(R), split-virion influenza vaccine, is used for
active immunization against influenza disease caused by the influenza subtypes
A and type B contained in the vaccine. FLUVIRAL(R) is indicated for the active
immunization against influenza caused by influenza virus in adults and
children 6 months of age or older.

    Important Safety Information

    Soreness at the injection site that can last up to 2 days is a common
side effect in adults, but rarely interferes with your daily activities. Flu
vaccines are safe and well tolerated in healthy children, but mild local
reactions, primarily soreness occurs in 7% of cases in children below 3 years
of age. Post-vaccination fever may be observed in 12% of children 1 to 5 years
of age. A flu vaccine may be contraindicated if you are allergic to eggs or if
you have acute febrile illness.

    GlaxoSmithKline: A Canadian Vaccines Leader

    GlaxoSmithKline is the leading Canadian influenza vaccine manufacturer,
and will supply the majority of the Canadian government's seasonal influenza
vaccines purchases until 2010. GlaxoSmithKline also has a contract with the
Government of Canada for the development and production of a pandemic
influenza vaccine, and to provide the infrastructure and capacity to produce
sufficient pandemic vaccine for Canadians in the event of an influenza
pandemic. GlaxoSmithKline maintains two state-of-the-art manufacturing
facilities dedicated to the production of innovative vaccines in Quebec City
and Laval, Quebec. GlaxoSmithKline's Laval site also serves as a research and
development hub for North America, providing activities related to research
projects in early development, as well as the implementation of technological
platforms supporting the pre-clinical and clinical development of candidate
vaccines.
    GlaxoSmithKline - one of the world's leading research-based
pharmaceutical and healthcare companies - is committed to improving the
quality of human life by enabling people to do more, feel better and live
longer.

    
    (R) Fluviral is a registered trademark, used under license by
        GlaxoSmithKline Inc.
    





For further information:

For further information: Media inquiries: Peter Schram, (905) 819-3363


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890